Krystal Biotech Inc (KRYS)

Inventory turnover

		Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020
Cost of revenue (ttm)	US$ in thousands	113,685	104,592	99,576	97,854	96,536	95,405	91,643	83,602	75,785	65,603	55,240	47,176	38,941	31,446	26,454	19,970	13,729	12,173	9,050	7,409
Inventory	US$ in thousands	26,508	18,581	12,179	11,037	6,985	5,278	1,100	—	0	—	—	—	—	—	—	—	—	—	—	—
Inventory turnover		4.29	5.63	8.18	8.87	13.82	18.08	83.31	—	—	—	—	—	—	—	—	—	—	—	—	—

December 31, 2024 calculation

Inventory turnover = Cost of revenue (ttm) ÷ Inventory
= $113,685K ÷ $26,508K
= 4.29

The inventory turnover ratio for Krystal Biotech Inc has shown a declining trend over the past several quarters. As of December 31, 2024, the inventory turnover ratio stands at 4.29, indicating that the company sells and replaces its inventory approximately 4.29 times a year.

A decreasing inventory turnover ratio can suggest inefficiencies in inventory management, such as overstocking or slow-moving inventory. It may also indicate challenges in sales and demand forecasting, leading to excess inventory levels.

A low inventory turnover ratio can tie up capital in excess inventory and potentially lead to increased holding costs and risk of obsolescence. It could also indicate potential challenges in generating sales and converting inventory into revenue.

Krystal Biotech Inc may need to review and optimize its inventory management practices to improve its inventory turnover ratio, increase operational efficiency, and enhance overall financial performance.